Literature DB >> 6414283

Effects of a commercial starch blocker preparation on carbohydrate digestion and absorption: in vivo and in vitro studies.

C B Hollenbeck, A M Coulston, R Quan, T R Becker, H J Vreman, D K Stevenson, G M Reaven.   

Abstract

We have tested the effectiveness of a commercial starch blocker on the digestion and absorption of dietary carbohydrates in six normal, healthy volunteers. The effectiveness of the starch blocker to attenuate or block the digestion of carbohydrate was assessed against a placebo by the measurement of end tidal breath hydrogen, plasma glucose, and insulin responses to a constant test meal. There were no significant differences in breath hydrogen, or plasma glucose and insulin responses. In vitro enzyme inhibition studies assessed the ability of the brush border enzyme maltase/glucoamylase to degrade starch in the presence of the starch blockers. A highly purified solution of rat and human maltase/glucoamylase was capable of degrading a starch solution, while 40 mM Tris-HCl (a known maltase/glucoamylase inhibitor) completely abolished the enzyme activity. These data challenge the claims that starch blocker preparations are effective in reducing or attenuating the absorption of carbohydrates or calories from a mixed meal. The ineffectiveness in vivo could be explained, in part, by the ability of the brush border enzyme maltase/glucoamylase to hydrolyze starch in the presence of starch blockers.

Entities:  

Mesh:

Substances:

Year:  1983        PMID: 6414283     DOI: 10.1093/ajcn/38.4.498

Source DB:  PubMed          Journal:  Am J Clin Nutr        ISSN: 0002-9165            Impact factor:   7.045


  5 in total

1.  Commercial soybean starch blocker consumption: impact on weight gain and on copper, lead and zinc status of rats.

Authors:  J Umoren; C Kies
Journal:  Plant Foods Hum Nutr       Date:  1992-04       Impact factor: 3.921

2.  ZnO nanoparticles and their acarbose-capped nanohybrids as inhibitors for human salivary amylase.

Authors:  Firdoz Shaik; Anil Kumar
Journal:  IET Nanobiotechnol       Date:  2017-04       Impact factor: 1.847

3.  The role of lipid and carbohydrate digestive enzyme inhibitors in the management of obesity: a review of current and emerging therapeutic agents.

Authors:  Sonia A Tucci; Emma J Boyland; Jason Cg Halford
Journal:  Diabetes Metab Syndr Obes       Date:  2010-05-10       Impact factor: 3.168

4.  Heterologous expression of an α-amylase inhibitor from common bean (Phaseolus vulgaris) in Kluyveromyces lactis and Saccharomyces cerevisiae.

Authors:  Stephanie Brain-Isasi; Alejandro Álvarez-Lueje; Thomas Joseph V Higgins
Journal:  Microb Cell Fact       Date:  2017-06-15       Impact factor: 5.328

Review 5.  Common bean (Phaseolus vulgaris L.) α-amylase inhibitors as safe nutraceutical strategy against diabetes and obesity: An update review.

Authors:  Stefania Peddio; Alessandra Padiglia; Faustina B Cannea; Roberto Crnjar; Wissam Zam; Javad Sharifi-Rad; Antonio Rescigno; Paolo Zucca
Journal:  Phytother Res       Date:  2022-04-29       Impact factor: 6.388

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.